A two-plasmid system for stable, selective-pressure-independent expression of multiple extracellular proteins in mycobacteria
Authors:
- 1 July 2004
- journal article
- Published by Microbiology Society in Microbiology
- Vol. 150 (7) , 2143-2151
Abstract
Recombinant mycobacteria expressing Mycobacterium tuberculosis extracellular proteins are leading candidates for new vaccines against tuberculosis and other mycobacterial diseases, and important tools both in antimycobacterial drug development and basic research in mycobacterial pathogenesis. Recombinant mycobacteria that stably overexpress and secrete major extracellular proteins of M. tuberculosis in native form on plasmids pSMT3 and pNBV1 were previously constructed by the authors. To enhance the versatility of this plasmid-based approach for mycobacterial protein expression, the Escherichia coli/mycobacteria shuttle plasmid pGB9 was modified to accommodate mycobacterial genes expressed from their endogenous promoters. Previous studies showed that the modified plasmid, designated pGB9.2, derived from the cryptic Mycobacterium fortuitum plasmid pMF1, was present at a low copy number in both E. coli and mycobacteria, and expression of recombinant M. tuberculosis proteins was found to be at levels paralleling its copy number, that is, approximating their endogenous levels. Plasmid pGB9.2 was compatible with the shuttle vectors pSMT3 and pNBV1 and in combination with them it simultaneously expressed the M. tuberculosis 30 kDa extracellular protein FbpB. Plasmid pGB9.2 was stably maintained in the absence of selective pressure in three mycobacterial species: Mycobacterium bovis BCG, M. tuberculosis and M. smegmatis. Plasmid pGB9.2 was found to be self-transmissible between both fast- and slow-growing mycobacteria, but not from mycobacteria to E. coli or between E. coli strains. The combination of two compatible plasmids in one BCG strain allows expression of recombinant mycobacterial proteins at different levels, a potentially important factor in optimizing vaccine potency.Keywords
This publication has 26 references indexed in Scilit:
- A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary TuberculosisInfection and Immunity, 2003
- Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technologyProceedings of the National Academy of Sciences, 2002
- An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the Mycobacterium tuberculosis 30 kda major secretory protein (antigen 85B), a mycolyl transferase11Edited by I. A. WilsonJournal of Molecular Biology, 2001
- A new single-copy mycobacterial plasmid, pMF1, from Mycobacterium fortuitum which is compatible with the pAL5000 replicon The EMBL accession number for the sequence determined in this work is AJ238973.Microbiology, 2000
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- Isolation by genetic labeling of a new mycobacterial plasmid, pJAZ38, from Mycobacterium fortuitumJournal of Bacteriology, 1997
- Role of the Major Antigen of Mycobacterium tuberculosis in Cell Wall BiogenesisScience, 1997
- Two independent type III secretion mechanisms for YopE in Yersinia enterocoliticaMolecular Microbiology, 1997
- Glutamine synthetase of Mycobacterium tuberculosis: extracellular release and characterization of its enzymatic activity.Proceedings of the National Academy of Sciences, 1994
- Transformation of mycobacterial species using hygromycin resistance as selectable markerMicrobiology, 1994